ASRT
Price
$0.78
Change
+$0.02 (+2.63%)
Updated
Dec 3 closing price
Capitalization
75.06M
97 days until earnings call
Intraday BUY SELL Signals
TXMD
Price
$1.59
Change
+$0.14 (+9.59%)
Updated
Dec 3, 04:59 PM (EDT)
Capitalization
17.59M
Intraday BUY SELL Signals
Interact to see
Advertisement

ASRT vs TXMD

Header iconASRT vs TXMD Comparison
Open Charts ASRT vs TXMDBanner chart's image
Assertio Holdings
Price$0.78
Change+$0.02 (+2.63%)
Volume$218.66K
Capitalization75.06M
TherapeuticsMD
Price$1.59
Change+$0.14 (+9.59%)
Volume$200
Capitalization17.59M
ASRT vs TXMD Comparison Chart in %
ASRT
Daily Signal:
Gain/Loss:
TXMD
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ASRT vs. TXMD commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ASRT is a Hold and TXMD is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 04, 2025
Stock price -- (ASRT: $0.76 vs. TXMD: $1.46)
Brand notoriety: ASRT and TXMD are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ASRT: 49% vs. TXMD: 13%
Market capitalization -- ASRT: $75.06M vs. TXMD: $18.4M
ASRT [@Pharmaceuticals: Generic] is valued at $75.06M. TXMD’s [@Pharmaceuticals: Generic] market capitalization is $18.4M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ASRT’s FA Score shows that 0 FA rating(s) are green whileTXMD’s FA Score has 1 green FA rating(s).

  • ASRT’s FA Score: 0 green, 5 red.
  • TXMD’s FA Score: 1 green, 4 red.
According to our system of comparison, TXMD is a better buy in the long-term than ASRT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ASRT’s TA Score shows that 2 TA indicator(s) are bullish while TXMD’s TA Score has 4 bullish TA indicator(s).

  • ASRT’s TA Score: 2 bullish, 7 bearish.
  • TXMD’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, TXMD is a better buy in the short-term than ASRT.

Price Growth

ASRT (@Pharmaceuticals: Generic) experienced а +5.81% price change this week, while TXMD (@Pharmaceuticals: Generic) price change was -9.88% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +3.67%. For the same industry, the average monthly price growth was +0.42%, and the average quarterly price growth was +25.91%.

Reported Earning Dates

ASRT is expected to report earnings on Mar 11, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+3.67% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ASRT($75.1M) has a higher market cap than TXMD($17.6M). TXMD YTD gains are higher at: 69.767 vs. ASRT (-13.305). TXMD has higher annual earnings (EBITDA): -1.37M vs. ASRT (-8.66M). ASRT has more cash in the bank: 98.2M vs. TXMD (6.07M). TXMD has less debt than ASRT: TXMD (6.6M) vs ASRT (39.9M). ASRT has higher revenues than TXMD: ASRT (117M) vs TXMD (2.56M).
ASRTTXMDASRT / TXMD
Capitalization75.1M17.6M427%
EBITDA-8.66M-1.37M632%
Gain YTD-13.30569.767-19%
P/E RatioN/A152.00-
Revenue117M2.56M4,572%
Total Cash98.2M6.07M1,618%
Total Debt39.9M6.6M604%
FUNDAMENTALS RATINGS
ASRT vs TXMD: Fundamental Ratings
ASRT
TXMD
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
72
Overvalued
80
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9691
PRICE GROWTH RATING
1..100
6238
P/E GROWTH RATING
1..100
9930
SEASONALITY SCORE
1..100
7550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ASRT's Valuation (72) in the Pharmaceuticals Major industry is in the same range as TXMD (80) in the Pharmaceuticals Generic industry. This means that ASRT’s stock grew similarly to TXMD’s over the last 12 months.

ASRT's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as TXMD (100) in the Pharmaceuticals Generic industry. This means that ASRT’s stock grew similarly to TXMD’s over the last 12 months.

TXMD's SMR Rating (91) in the Pharmaceuticals Generic industry is in the same range as ASRT (96) in the Pharmaceuticals Major industry. This means that TXMD’s stock grew similarly to ASRT’s over the last 12 months.

TXMD's Price Growth Rating (38) in the Pharmaceuticals Generic industry is in the same range as ASRT (62) in the Pharmaceuticals Major industry. This means that TXMD’s stock grew similarly to ASRT’s over the last 12 months.

TXMD's P/E Growth Rating (30) in the Pharmaceuticals Generic industry is significantly better than the same rating for ASRT (99) in the Pharmaceuticals Major industry. This means that TXMD’s stock grew significantly faster than ASRT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ASRTTXMD
RSI
ODDS (%)
Bearish Trend 7 days ago
78%
Bearish Trend 7 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 7 days ago
78%
Bearish Trend 7 days ago
87%
Momentum
ODDS (%)
Bearish Trend 7 days ago
80%
Bullish Trend 7 days ago
73%
MACD
ODDS (%)
Bearish Trend 7 days ago
80%
Bearish Trend 7 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 7 days ago
81%
Bearish Trend 7 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 7 days ago
83%
Bullish Trend 7 days ago
65%
Advances
ODDS (%)
Bullish Trend 7 days ago
82%
Bullish Trend 7 days ago
69%
Declines
ODDS (%)
Bearish Trend 11 days ago
83%
Bearish Trend 10 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 7 days ago
77%
Bearish Trend 7 days ago
90%
Aroon
ODDS (%)
Bearish Trend 7 days ago
84%
Bullish Trend 7 days ago
62%
View a ticker or compare two or three
Interact to see
Advertisement
ASRT
Daily Signal:
Gain/Loss:
TXMD
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SLAB129.472.83
+2.23%
Silicon Laboratories
JBDI0.890.01
+1.50%
JBDI Holdings Ltd
PAYX110.750.21
+0.19%
Paychex
SANG5.19-0.01
-0.29%
Sangoma Technologies Corp
HPK6.50-0.38
-5.52%
HighPeak Energy

ASRT and

Correlation & Price change

A.I.dvisor tells us that ASRT and ANIK have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ASRT and ANIK's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ASRT
1D Price
Change %
ASRT100%
-3.19%
ANIK - ASRT
31%
Poorly correlated
-3.33%
HROW - ASRT
29%
Poorly correlated
+0.98%
SNOA - ASRT
28%
Poorly correlated
-1.55%
CPHI - ASRT
26%
Poorly correlated
+5.52%
LFCR - ASRT
26%
Poorly correlated
-1.15%
More

TXMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, TXMD has been loosely correlated with LIEN. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if TXMD jumps, then LIEN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TXMD
1D Price
Change %
TXMD100%
-3.95%
LIEN - TXMD
36%
Loosely correlated
+1.26%
ASRT - TXMD
27%
Poorly correlated
-3.19%
ACB - TXMD
23%
Poorly correlated
-0.99%
SCYX - TXMD
22%
Poorly correlated
-2.57%
SBFM - TXMD
22%
Poorly correlated
+5.01%
More